Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

Official Title

Analysis of Bronchial and Bronchoalveolar Lavage Fluid and Bronchial Mucosal Biopsies in Patients With Wegener's Granulomatosis

Brief Summary

      This study will collect fluid and tissue samples from the bronchi (air passages to the lungs)
      of patients with Wegener's granulomatosis for laboratory examination. Wegener's
      granulomatosis is a type of vasculitis (blood vessel inflammation) that can affect many parts
      of the body, including the brain, nerves, eyes, skin, sinuses, kidneys, intestinal tract,
      joints, heart, lungs and other sites. About 85 percent of patients have lung involvement. The
      lining of the bronchi (bronchial mucosa) is composed of cells that produce mucus,
      inflammatory cells, and inflammatory mediators (chemicals produced in response to
      inflammation). Analysis of these various substances may provide insight into what causes
      different types of lung problems in Wegener's granulomatosis.

      Patients between 18 and 75 years of age with Wegener's granulomatosis who require
      bronchoscopy to evaluate the cause of their lung problem may be eligible for this study.

      Participants will undergo a bronchoscopy in the hospital intensive care unit (ICU). For this
      procedure, the mouth and throat are numbed with lidocaine jelly and spray. If needed, a
      sedative is given for comfort. A small plastic tube (intravenous catheter) is placed in a
      vein to give medications. A pencil-thin tube is then placed through the nose or mouth into
      the lung airways to examine the airways carefully.

      At the time of the bronchoscopy, patients in this study will undergo the following additional

        -  Bronchoalveolar lavage - Saline (salt water) is injected through the bronchoscope into
           the air passage, acting as a rinse. A sample of the fluid is then withdrawn and examined
           for infection, inflammatory cells and inflammatory chemicals. (This may be done as part
           of the standard medical care procedure.)

        -  Bronchial lavage - This procedure is similar to bronchoalveolar lavage, but less fluid
           is used to rinse larger airways.

        -  Bronchial mucosal biopsies - A small wire is inserted through the bronchoscope next to
           the bronchial lining. Forceps at the end of the wire pinch off a small piece of tissue
           for withdrawal and examination.

      The patient's heart rhythm and rate and oxygen levels are monitored during the procedure.
      When the procedures are finished, the patient is monitored in the ICU until the numbing
      effect of the anesthetic has worn off and then moves to a regular hospital bed for overnight.

      Patients whose test results show an isolated infection or isolated Wegener's lung tissue
      involvement and who are being treated or are eligible for treatment under another NIH
      protocol will be followed by X-ray for improvement of their infection or other lung
      involvement with treatment. Patients whose infection or lung tissue involvement improves may
      be asked to undergo a second bronchoscopy as described above, but for research purposes only.

Detailed Description

      Wegener's granulomatosis is a systemic vasculitis in which parenchymal and/or endobronchial
      inflammation frequently occur. The purpose of this investigation is to analyze bronchial and
      bronchoalveolar lavage fluid in patients with Wegener's granulomatosis for the presence of
      immunoregulatory mediators and pro-inflammatory cytokines. We will also be examining mucosal
      biopsies in these patients to define the histologic changes, the phenotype of infiltrating
      leukocytes, and the pattern of adhesion molecule expression that may be present. Such studies
      could lead to an improved understanding of the pathophysiology of this disease and of its
      pulmonary manifestations and provide potential directions for future therapy.

Study Type





* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

April 1996

Completion Date

January 2003

Eligibility Criteria


        Diagnosis of Wegener's granulomatosis based on clinical and histological characteristics.

        Age between 18-75 years.

        Bronchoscopy is required as part of their standard medical care.

        FEV1 is greater than 55 percent of FVC.

        O2 saturation is greater than 90 percent.


        FEV1 is less than 55% of FVC.

        O2 saturation is less than 90%.

        Abnormal PT, PTT, or platelet count less than 50.

        History of adverse reaction to lidocaine or other local anesthetics.





N/A - N/A

Accepts Healthy Volunteers



, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Study Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Study Sponsor

, , 

Verification Date

January 2003